TW552260B - Endothelin antagonists - Google Patents
Endothelin antagonists Download PDFInfo
- Publication number
- TW552260B TW552260B TW087112783A TW87112783A TW552260B TW 552260 B TW552260 B TW 552260B TW 087112783 A TW087112783 A TW 087112783A TW 87112783 A TW87112783 A TW 87112783A TW 552260 B TW552260 B TW 552260B
- Authority
- TW
- Taiwan
- Prior art keywords
- trans
- group
- ethyl
- butyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/905,913 US6162927A (en) | 1994-08-19 | 1997-08-04 | Endothelin antagonists |
| US4895598A | 1998-03-27 | 1998-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW552260B true TW552260B (en) | 2003-09-11 |
Family
ID=26726720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW087112783A TW552260B (en) | 1997-08-04 | 1998-08-10 | Endothelin antagonists |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1003740A2 (hu) |
| JP (1) | JP2001512119A (hu) |
| CN (1) | CN1301264A (hu) |
| AU (1) | AU748469B2 (hu) |
| BG (1) | BG104216A (hu) |
| BR (1) | BR9815296A (hu) |
| CA (1) | CA2297894A1 (hu) |
| HU (1) | HUP0003484A3 (hu) |
| IL (1) | IL134175A0 (hu) |
| NO (1) | NO20000542L (hu) |
| NZ (1) | NZ502395A (hu) |
| PL (1) | PL342500A1 (hu) |
| SK (1) | SK1452000A3 (hu) |
| TR (4) | TR200101234T2 (hu) |
| TW (1) | TW552260B (hu) |
| WO (1) | WO1999006397A2 (hu) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000004179A1 (en) * | 1998-07-15 | 2000-01-27 | Bristol-Myers Squibb Company | Stereoselective reductive amination of ketones |
| TWI306760B (en) | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
| JPWO2002051836A1 (ja) * | 2000-12-27 | 2004-04-22 | 協和醗酵工業株式会社 | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| IL158071A0 (en) * | 2001-04-11 | 2004-03-28 | Abbott Lab | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| FR2874015B1 (fr) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| WO2007034406A1 (en) * | 2005-09-22 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin |
| JP2010536880A (ja) | 2007-08-22 | 2010-12-02 | ギリード・コロラド・インコーポレーテッド | 糖尿病の合併症のための療法 |
| WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| CA2850166C (en) | 2011-09-27 | 2019-12-03 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
| WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014134201A1 (en) | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| CA2906538C (en) | 2013-03-14 | 2021-02-02 | Ana Gonzalez Buenrostro | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| CN104262329A (zh) * | 2014-10-22 | 2015-01-07 | 南京友杰医药科技有限公司 | 反式阿曲生坦的制备 |
| WO2024022262A1 (zh) * | 2022-07-25 | 2024-02-01 | 深圳信立泰药业股份有限公司 | 一种内皮素a(eta)受体拮抗剂化合物的盐及其制备方法和医药用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013842A (en) * | 1990-01-22 | 1991-05-07 | Monsanto Company | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors |
| ATE219077T1 (de) * | 1994-08-19 | 2002-06-15 | Abbott Lab | Endothelin antagoniste |
| CZ253698A3 (cs) * | 1996-02-13 | 1999-03-17 | Abbott Laboratories | Deriváty 4-(benzo-1,3-dioxolyl)-pyrrolidin-3-karboxylové kyseliny jako antagonisté endothelinu |
| US5618949A (en) * | 1996-07-12 | 1997-04-08 | Abbott Laboratories | Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds |
-
1998
- 1998-07-27 PL PL98342500A patent/PL342500A1/xx not_active Application Discontinuation
- 1998-07-27 SK SK145-2000A patent/SK1452000A3/sk unknown
- 1998-07-27 TR TR2001/01234T patent/TR200101234T2/xx unknown
- 1998-07-27 TR TR2001/01233T patent/TR200101233T2/xx unknown
- 1998-07-27 HU HU0003484A patent/HUP0003484A3/hu unknown
- 1998-07-27 WO PCT/US1998/015479 patent/WO1999006397A2/en not_active Application Discontinuation
- 1998-07-27 JP JP2000505155A patent/JP2001512119A/ja active Pending
- 1998-07-27 TR TR2005/01137T patent/TR200501137T2/xx unknown
- 1998-07-27 CA CA002297894A patent/CA2297894A1/en not_active Abandoned
- 1998-07-27 NZ NZ502395A patent/NZ502395A/xx unknown
- 1998-07-27 BR BR9815296-3A patent/BR9815296A/pt not_active Application Discontinuation
- 1998-07-27 CN CN98809462A patent/CN1301264A/zh active Pending
- 1998-07-27 TR TR2000/00993T patent/TR200000993T2/xx unknown
- 1998-07-27 IL IL13417598A patent/IL134175A0/xx unknown
- 1998-07-27 AU AU85921/98A patent/AU748469B2/en not_active Ceased
- 1998-07-27 EP EP98937139A patent/EP1003740A2/en not_active Ceased
- 1998-08-10 TW TW087112783A patent/TW552260B/zh not_active IP Right Cessation
-
2000
- 2000-02-02 NO NO20000542A patent/NO20000542L/no not_active Application Discontinuation
- 2000-03-02 BG BG104216A patent/BG104216A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2297894A1 (en) | 1999-02-11 |
| AU8592198A (en) | 1999-02-22 |
| SK1452000A3 (en) | 2001-05-10 |
| HUP0003484A2 (hu) | 2002-01-28 |
| CN1301264A (zh) | 2001-06-27 |
| IL134175A0 (en) | 2001-04-30 |
| TR200501137T2 (tr) | 2005-12-21 |
| BR9815296A (pt) | 2001-11-20 |
| JP2001512119A (ja) | 2001-08-21 |
| AU748469B2 (en) | 2002-06-06 |
| TR200000993T2 (tr) | 2000-12-21 |
| WO1999006397A2 (en) | 1999-02-11 |
| NO20000542D0 (no) | 2000-02-02 |
| TR200101233T2 (tr) | 2002-06-21 |
| PL342500A1 (en) | 2001-06-04 |
| HUP0003484A3 (en) | 2002-02-28 |
| TR200101234T2 (tr) | 2002-06-21 |
| NO20000542L (no) | 2000-04-04 |
| EP1003740A2 (en) | 2000-05-31 |
| NZ502395A (en) | 2002-08-28 |
| WO1999006397A3 (en) | 1999-12-09 |
| BG104216A (bg) | 2000-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW552260B (en) | Endothelin antagonists | |
| TWI344955B (en) | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient | |
| DE69735710T2 (de) | Neue benzo-1,3-dioxolyl-und benzofuranyl substituierte pyrrolidinederivate als endothelin antagonisten | |
| US6380241B1 (en) | Treatment of diseases using endothelin antagonists | |
| NL1028193C2 (nl) | Farmaceutisch werkzame verbindingen. | |
| HU230248B1 (hu) | N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok | |
| CZ301161B6 (cs) | Piperidinopiperidylový derivát užitecný jako CCR5 antagonista, farmaceutický prostredek jej obsahující | |
| TW200908963A (en) | Novel compounds | |
| CA2932010A1 (en) | Urea derivative or pharmacologically acceptable salt thereof | |
| IL134905A (en) | Intermediates for endothelin antagonistic pyrrolidine derivatives, their preparation and pharmaceutical compositions comprising them | |
| TW200528101A (en) | Chemical compounds | |
| US6946481B1 (en) | Endothelin antagonists | |
| CA2917965A1 (fr) | Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| JP2022188014A (ja) | バニン阻害剤としてのヘテロ芳香族化合物 | |
| WO2021231474A1 (en) | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | |
| US7208517B1 (en) | Endothelin antagonists | |
| WO2002017912A1 (en) | Endothelin antagonists | |
| US7365093B2 (en) | Endothelin antagonists | |
| BR112018008204B1 (pt) | Composto, composição farmacêutica, e, método para tratamento de distúrbios associados com irregularidades da transmissão de sinal glutamatérgico e de distúrbios do sistema nervoso central | |
| JPH111472A (ja) | ベンズアミド誘導体及びそれを含有する医薬組成物 | |
| TW201038562A (en) | Azetidines as histamine H3 receptor antagonists | |
| TW581760B (en) | Pyprolidine carboxylic acid derivatives having endothelin antagonism | |
| AU781355B2 (en) | Novel benzo-1,3-dioxolyl-and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists | |
| KR100848490B1 (ko) | 베타아미노기를 갖는 1,2,5-트리아제판 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 | |
| AU2005201160B2 (en) | Endothelin antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |